Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
Top Cited Papers
Open Access
- 9 November 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 540 (7632), 284-287
- https://doi.org/10.1038/nature20583
Abstract
A combination of therapeutic vaccination with Ad26/MVA and stimulation of innate immune responses leads to improved virologic control and delayed rebound in SIV-infected macaques following discontinuation of antiretroviral therapy. These authors demonstrate that combining an experimental vaccine—consisting of an adenovirus serotype 26 vector vaccine and an MVA vector vaccine (Ad26/MVA)—with the innate immune stimulant Toll-like receptor 7 leads to improved virologic control and delayed rebound following discontinuation of stable antiretroviral therapy in SIV-infected macaques. The development of immunologic interventions that can target the viral reservoir in HIV-1-infected individuals is a major goal of HIV-1 research1,2. However, little evidence exists that the viral reservoir can be sufficiently targeted to improve virologic control following discontinuation of antiretroviral therapy. Here we show that therapeutic vaccination with Ad26/MVA (recombinant adenovirus serotype 26 (Ad26) prime, modified vaccinia Ankara (MVA) boost)3,4 and stimulation of TLR7 (Toll-like receptor 7) improves virologic control and delays viral rebound following discontinuation of antiretroviral therapy in SIV-infected rhesus monkeys that began antiretroviral therapy during acute infection. Therapeutic vaccination with Ad26/MVA resulted in a marked increase in the magnitude and breadth of SIV-specific cellular immune responses in virologically suppressed, SIV-infected monkeys. TLR7 agonist administration led to innate immune stimulation and cellular immune activation. The combination of Ad26/MVA vaccination and TLR7 stimulation resulted in decreased levels of viral DNA in lymph nodes and peripheral blood, and improved virologic control and delayed viral rebound following discontinuation of antiretroviral therapy. The breadth of cellular immune responses correlated inversely with set point viral loads and correlated directly with time to viral rebound. These data demonstrate the potential of therapeutic vaccination combined with innate immune stimulation as a strategy aimed at a functional cure for HIV-1 infection.Keywords
This publication has 33 references indexed in Scilit:
- Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutationsNature, 2015
- Absence of Detectable HIV-1 Viremia after Treatment Cessation in an InfantNew England Journal of Medicine, 2013
- Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus MonkeysJournal of Virology, 2010
- Current Estimates for HIV-1 Production Imply Rapid Viral Clearance in Lymphoid TissuesPLoS Computational Biology, 2010
- Dynamics of Immune Escape during HIV/SIV InfectionPLoS Computational Biology, 2008
- Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaquesProceedings of the National Academy of Sciences of the United States of America, 2007
- Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysisMathematical Biosciences, 2001
- Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresisThe Lancet, 1999
- Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyNature Medicine, 1999
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyProceedings of the National Academy of Sciences of the United States of America, 1997